Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Hadji, P., Aapro, M.S., Body, J-J. et al. (18 more authors) (2017) Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. Journal of Bone Oncology, 7. pp. 1-12. ISSN 2212-1374

Abstract

Metadata

Authors/Creators:
  • Hadji, P.
  • Aapro, M.S.
  • Body, J-J.
  • Gnant, M.
  • Brandi, M.L.
  • Reginster, J.Y.
  • Zillikens, M.C.
  • Glüer, C-C.
  • de Villiers, T.
  • Baber, R.
  • Roodman, G.D.
  • Cooper, C.
  • Langdahl, B.
  • Palacios, S.
  • Kanis, J.
  • Al-Daghri, N.
  • Nogues, X.
  • Eriksen, E.F.
  • Kurth, A.
  • Rizzoli, R.
  • Coleman, R.E. ORCID logo https://orcid.org/0000-0002-4275-1043
Copyright, Publisher and Additional Information: © 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Keywords: Bisphosphonate; Breast cancer; Denosumab; Endocrine treatment; Fracture; Osteoporosis
Dates:
  • Published (online): 23 March 2017
  • Accepted: 10 March 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 01 Jun 2017 15:22
Last Modified: 01 Jun 2017 15:22
Published Version: http://doi.org/10.1016/j.jbo.2017.03.001
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.jbo.2017.03.001
Related URLs:

Share / Export

Statistics